46,570 Shares in Waters Corporation $WAT Purchased by Distillate Capital Partners LLC

Distillate Capital Partners LLC acquired a new stake in Waters Corporation (NYSE:WAT) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 46,570 shares of the medical instruments supplier’s stock, valued at approximately $13,962,000.

Other institutional investors also recently modified their holdings of the company. Root Financial Partners LLC bought a new stake in shares of Waters during the third quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd acquired a new position in Waters during the 3rd quarter worth $26,000. Hantz Financial Services Inc. lifted its holdings in Waters by 115.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 60 shares in the last quarter. CYBER HORNET ETFs LLC bought a new position in Waters in the 2nd quarter valued at $53,000. Finally, Versant Capital Management Inc increased its stake in shares of Waters by 510.3% in the 3rd quarter. Versant Capital Management Inc now owns 177 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 148 shares during the period. 94.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on WAT. Bank of America cut their price target on Waters from $410.00 to $350.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Robert W. Baird set a $363.00 price objective on Waters in a report on Tuesday, February 10th. Weiss Ratings restated a “hold (c)” rating on shares of Waters in a research report on Wednesday, January 21st. HSBC started coverage on shares of Waters in a research report on Tuesday, January 27th. They set a “buy” rating and a $460.00 price target for the company. Finally, UBS Group decreased their target price on Waters from $395.00 to $370.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.84.

Waters Price Performance

Shares of NYSE WAT opened at $286.42 on Monday. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. The business’s 50 day moving average price is $352.67 and its two-hundred day moving average price is $351.58. The company has a market cap of $28.10 billion, a PE ratio of 26.59, a price-to-earnings-growth ratio of 1.97 and a beta of 1.20. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15.

Waters (NYSE:WAT) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping analysts’ consensus estimates of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The firm had revenue of $932.36 million during the quarter, compared to analysts’ expectations of $928.17 million. During the same period in the previous year, the business posted $4.10 earnings per share. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, analysts predict that Waters Corporation will post 12.86 EPS for the current year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.